Edesa Biotech Inc(EDSA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:00 PM ET (Korea 10/28 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.69 | Insider Own | 13.48% | Shs Outstand | 13.5M | Perf Week | -6.74% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | -4.03% | Insider Trans | - | Shs Float | 11.7M | Perf Month | -27.95% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | -0.58 | Inst Own | 37.97% | Short Float | 1.38% | Perf Quarter | -50.93% |
| Income | -0.01B | P/S | - | EPS this Y | -56.43% | Inst Trans | 7.53% | Short Ratio | 2.66 | Perf Half Y | -81.56% |
| Sales | 0.00B | P/B | 63.5 | EPS next 5Y | -17.31% | ROA | -102.46% | Short Interest | 0.16M | Perf YTD | 85.21% |
| Book/sh | 0.04 | P/C | 3.44 | EPS past 3/5Y | -6.32% -11.35% | ROE | -122.93% | 52W High | -87.06% ($20.32) | Perf Year | - |
| Cash/sh | 0.76 | P/FCF | - | Sales past 3/5Y | - | ROIC | -160.05% | 52W Low | 265.28% ($0.72) | Perf 3Y | -15.43% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -27.34% | Gross Margin | - | Volatility(W/M) | 8.42% 10.01% | Perf 5Y | -95.21% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.3 | Perf 10Y | -99.62% |
| Dividend Ex-Date | - | Quick Ratio | 2.76 | EPS Q/Q | -140.99% | Profit Margin | - | RSI (14) | 31.14 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.76 | Sales Q/Q | - | SMA20 | -17.36% ($3.18) | Beta | 1.23 | Target Price | $16.33 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/13 | SMA50 | -33.32% ($3.94) | Rel Volume | 0.42 | Prev Close | $2.59 |
| Employees | 17 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -37.93% - | SMA200 | -53.37% ($5.64) | Avg Volume(3M) | 0.06M | Price | $2.63 |
| IPO | 2010/6/21 | Option/Short | No/Yes | Trades | 145 | Volume | 25,665 | Change | 1.54% |
💉 Edesa Biotech () is a clinical-stage biotech developing host-based therapeutics that target inflammatory and immune diseases. The company has secured positive Phase 3 clinical results for its acute respiratory distress syndrome (ARDS) drug candidate (EB05), and is strengthening the development of its vitiligo treatment (EB06).
Over the past 1 year, on the lower side
87% below its 1-year high.
Traded less than usual. That is 42% of its average volume.
EDSA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -56.4% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -95.2%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 38.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #439 of 594 in the industry
Based on market cap of $36M.
NNVC#438 NanoViricides Inc $37M PER - EDSA#439 Edesa Biotech Inc $36M PER - 
ACET#440 Adicet Bio Inc $35M PER - 
EXOZ#441 eXoZymes Inc $35M PER - 
LITS#442 Lite Strategy Inc $35M PER - 
FAQ
What kind of company is EDSA?
EDSA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of EDSA?
The market cap of EDSA is approximately $36M, ranking 5,015 within its sector.
What is the 52-week high and low for EDSA?
EDSA has recorded a 52-week high of $20.32 and a low of $0.72.
